Adicet Bio
ACET
56 hedge funds and large institutions have $169M invested in Adicet Bio in 2019 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 27 increasing their positions, 6 reducing their positions, and 2 closing their positions.
400% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 2
350% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 6
17% more funds holding
Funds holding: 48 → 56 (+8)
0.01% more ownership
Funds ownership: 0.46% → 0.47% (+0.01%)
10% less capital invested
Capital invested by funds: $189M → $169M (-$19.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HighTower Advisors
Chicago,
Illinois
|
+$1.5M |
| 2 |
PSP
Principal Street Partners
Memphis,
Tennessee
|
+$1.5M |
| 3 |
AG
Artal Group
Luxembourg
|
+$1.4M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$654K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$1.83M |
| 2 |
DAM
Deltec Asset Management
New York
|
-$789K |
| 3 |
RL
Ruffer LLP
London,
United Kingdom
|
-$674K |
| 4 |
BFM
Boothbay Fund Management
New York
|
-$264K |
| 5 |
Citigroup
New York
|
-$33.5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
51
Tower Research Capital (TRC)
New York
| $4K | +$4.47K | +4 | New |
|
|
MAM
52
Meeder Asset Management
Dublin,
Ohio
| $3K | – | – | – |
|
|
CIAS
53
Capital Investment Advisory Services
Raleigh,
North Carolina
| $2K | – | – | – |
|
54
Daiwa Securities Group
Tokyo,
Japan
| $2K | – | – | – |
|
55
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| $2K | – | – | – |
|
56
Royal Bank of Canada
Toronto,
Ontario, Canada
| $1K | +$1.12K | +1 | New |
|
|
DAM
57
Deltec Asset Management
New York
| – | -$789K | -690 | Closed |
|
|
BFM
58
Boothbay Fund Management
New York
| – | -$264K | -231 | Closed |
|
ACET Hedge Fund Activity: Q3 2019 in Review
56 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in Adicet Bio (ACET) for Q3 2019, worth a combined $169M — down 10% from $189M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new ACET positions and 2 closed out — a net gain of 8 holders — while 27 added to existing stakes and 6 trimmed.
The largest buyer was HighTower Advisors, opening a new position worth an estimated $1.5M. The largest seller was Jennison Associates, cutting an estimated $1.83M.
- 56 institutional investors held Adicet Bio (ACET) as of Q3 2019, up from 48 in Q2 2019.
- Funds reported $169M of Adicet Bio stock for Q3 2019, down 10% quarter-over-quarter.
- 10 funds opened new Adicet Bio positions in Q3 2019 and 2 closed out, a net change of +8 holders.
- The largest Adicet Bio buyer in Q3 2019 was HighTower Advisors, an estimated $1.5M added.
- The largest Adicet Bio seller in Q3 2019 was Jennison Associates, an estimated $1.83M sold.
Based on aggregated 13F filings for Q3 2019.